-
公开(公告)号：US20230139366A1
公开(公告)日：2023-05-04
申请号：US18047708
申请日：2022-10-19
Applicant: VICTORIA LINK LTD
Inventor： Amy Jane FOSTER , Bridget Louise Stocker , Mattheus Simon Maria Timmer , Sho Yamasaki
IPC: A61K39/39 , A61P37/04 , C07H15/18 , C07H13/08 , A61K31/7024
Abstract: The invention relates to brartemicin analogues of Formula IV and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
-
公开(公告)号：US20230096920A1
公开(公告)日：2023-03-30
申请号：US17957350
申请日：2022-09-30
Applicant: Victoria Link Ltd. , University of Kansas
IPC: A61K31/485 , A61P25/28
Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
-
公开(公告)号：US20220233668A1
公开(公告)日：2022-07-28
申请号：US17609641
申请日：2020-05-08
Inventor： Dale Ian GODFREY , William Ross HEATH , Lauren Eelise HOLZ , Ian Francis HERMANS , Gavin Frank PAINTER , Regan James ANDERSON , Benjamin Jason COPTON , Shivali Ashwin GULAB
IPC: A61K39/015 , A61P33/06
Abstract: The present invention generally relates to a glycopeptide conjugate compound of Formula (I):, as described herein, compositions comprising the conjugate compound and to the use of such a compound to as a vaccine.
-
公开(公告)号：US20210023074A1
公开(公告)日：2021-01-28
申请号：US16978571
申请日：2019-03-07
Applicant: Victoria Link Ltd. , University of Kansas
IPC: A61K31/485 , A61P25/28
Abstract: The present invention relates generally to methods of using nalmefene for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalmefene for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalmefene for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
-
公开(公告)号：US20160356644A1
公开(公告)日：2016-12-08
申请号：US15117598
申请日：2015-02-05
Applicant: VICTORIA LINK LTD
Inventor： Justin M. Hodgkiss , Kai Chen
IPC: G01J1/42
CPC classification number: G01J1/4228 , G01J3/0232 , G01J3/2889 , G01J3/4406 , G01J2003/4424 , G01N21/636 , G01N21/6408 , G01N21/65 , G01N2201/061 , G01N2201/0696
Abstract: A transient grating (TG) is used as an optical gating element with sub-picosecond time resolution for luminescence measurements from a photo-detector array. The transient grating is formed in a gate medium by one or more pulsed gate beams. For photoluminescence measurements such as photoluminescence spectroscopy or imaging, a source is excited by a pulsed excitation beam, and the pulsed gate beams are synchronized to the pulsed excitation beam with an adjustable delay between the excitation of the source and the formation of the TG. Moreover, a source or its spectra can be imaged at two different regions of the photo-detector array at two different times spaced in time by a selected duration of time with sub-picosecond resolution over a range of a nanosecond or more. A beam from the source is deflected to the different regions by changing the frequency or geometry of the pulsed gate beams.
Abstract translation: 瞬态光栅（TG）被用作具有亚皮秒时间分辨率的来自光电检测器阵列的发光测量的光学门控元件。 瞬态光栅通过一个或多个脉冲栅极波束在栅极介质中形成。 对于诸如光致发光光谱或成像的光致发光测量，源通过脉冲激发光束激发，并且脉冲栅极光束与脉冲激发光束同步，在源的激发和TG的形成之间具有可调节的延迟。 此外，源或其光谱可以在光检测器阵列的两个不同的区域以两分之一的时间在一个纳秒或更多的范围内以一定的时间间隔以亚皮秒分辨率成像。 来自源极的光束通过改变脉冲栅极的频率或几何形状而偏转到不同的区域。
-
Patent Agency Ranking
公开(公告)号：US20210015813A1
公开(公告)日：2021-01-21
申请号：US16978542
申请日：2019-03-07
Applicant: Victoria Link Ltd. , University of Kansas
IPC: A61K31/485 , A61P25/28
Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
-
公开(公告)号：US09752927B2
公开(公告)日：2017-09-05
申请号：US15117598
申请日：2015-02-05
Applicant: VICTORIA LINK LTD
Inventor： Justin M. Hodgkiss , Kai Chen
CPC classification number: G01J1/4228 , G01J3/0232 , G01J3/2889 , G01J3/4406 , G01J2003/4424 , G01N21/636 , G01N21/6408 , G01N21/65 , G01N2201/061 , G01N2201/0696
Abstract: A transient grating (TG) is used as an optical gating element with sub-picosecond time resolution for luminescence measurements from a photo-detector array. The transient grating is formed in a gate medium by one or more pulsed gate beams. For photoluminescence measurements such as photoluminescence spectroscopy or imaging, a source is excited by a pulsed excitation beam, and the pulsed gate beams are synchronized to the pulsed excitation beam with an adjustable delay between the excitation of the source and the formation of the TG. Moreover, a source or its spectra can be imaged at two different regions of the photo-detector array at two different times spaced in time by a selected duration of time with sub-picosecond resolution over a range of a nanosecond or more. A beam from the source is deflected to the different regions by changing the frequency or geometry of the pulsed gate beams.
-
公开(公告)号：US11510980B2
公开(公告)日：2022-11-29
申请号：US16761027
申请日：2018-11-02
Applicant: VICTORIA LINK LTD , OSAKA UNIVERSITY
Inventor： Amy Jane Foster , Bridget Louise Stocker , Mattheus Simon Maria Timmer , Sho Yamasaki
IPC: A61P37/04 , C07H13/08 , A61K31/7024 , A61K39/39 , C07H15/18
Abstract: The invention relates to brartemicin analogues of Formula (IV) and their uses. These compounds are potent Mincle agonists and Th1-stimulating vaccine adjuvants.
-
公开(公告)号：US11324742B2
公开(公告)日：2022-05-10
申请号：US16936975
申请日：2020-07-23
Applicant: Victoria Link Ltd. , University of Kansas
IPC: A61K31/485 , A61P25/28
Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
-
公开(公告)号：US11035598B2
公开(公告)日：2021-06-15
申请号：US15324617
申请日：2015-07-06
Applicant: VICTORIA LINK LTD
Inventor： Michael Staines
Abstract: A thermally insulated vessel contains a thermal insulation barrier defining an upper compartment above the barrier and a lower compartment below the barrier. The compartments are interconnected by a passage to allow pressure equalization. High temperature superconductor is mounted within the lower compartment for immersion in the liquid cryogen. A cryogenic refrigerator has a cold head thermally coupled to the high temperature superconductor for maintaining the high temperature superconductor below a superconductive transition temperature. A temperature controller maintains a temperature of the liquid cryogen in the upper compartment at a temperature of at least a boiling point of the liquid cryogen at atmospheric pressure when the lower compartment and at least a portion of the upper compartment are filled with the liquid cryogen.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.019 seconds)
